Every year, May 8 is celebrated as World Ovarian Cancer Day to raise awareness regarding the Ovarian Cancer. This day aims at creating a community where those living with ovarian cancer, survivors, and their families and friends can unite, share their experiences, and help educate the public about this deadly disease.
According to the Globocan, the incidence of ovarian cancer was 24,469 cases in the United States in 2018. Ovarian cancer has the lowest survival rate in comparison to the other female cancers. Five-year ovarian cancer survival rates range from 30% to 45% worldwide. The majority of the women are diagnosed at the advanced stage in which cancer has already spread to other body parts and, makes it more difficult to treat. It is difficult to diagnose ovarian cancer as its symptoms are often confused with symptoms of other less severe illnesses, particularly gastrointestinal complaints.
May is the Bladder Cancer Awareness month to raise awareness regarding types, etiology, risk factors, diagnosis, treatment, and preventative measures for Bladder Cancer.
Bladder Cancer is the most common cancer which includes the uncontrollable cell growth in the urinary bladder and spreads to the other parts of the body. According to the Surveillance, Epidemiology, and End Results (SEER), the incidence cases of Bladder Cancer is expected to be 81,400 in 2020. Around 17,980 people are expected to die due to Bladder Cancer in 2020.
According to the Bladder Cancer Advocacy Network (BCAN), the May Bladder Cancer Awareness month includes:
Discussing the cancer journey and sharing the story
Telling others about the symptoms
Encouraging friends, co-workers, and family members to take a non-invasive bladder cancer urine test
Participating in one or more bladder cancer month events
Globally, the coronavirus (COVID-19) pandemic outbreak has shown a drastic impact on the diagnostic companies resulting in a shortage of reagent, new product launch, and developing a pipeline. To combat the situation, FDA has been working continuously to facilitate the development and availability of medical and diagnostic products, for use by patients, physicians, and healthcare to expedite the diagnosis process as quickly as possible.
Hence, Food and Drug Administration (FDA) provides the Emergency Use Authorizations (EUAs), to diagnostic companies to help make medical and diagnostic products available as quickly as possible to treat or diagnosis the chronic or life-threatening disease during public health emergencies.
Several companies such as Abbott Laboratories, Hologic, Quidel Corp, and Roche Diagnostics have received emergency use authorization from the Food and Drug Administration (FDA) for their COVID-19 diagnostic assays for ramping up production to help alleviate testing shortages. The molecular diagnostic tests are generally authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in specific upper and lower respiratory specimens from individuals suspected of COVID-19 by their healthcare provider. The specific specimen types for each test can be found in the authorization letter.
Some molecular diagnostic tests
may require a highly experienced expertise to manually perform the test (e.g.,
perform an RNA extraction step usually using specific extraction platforms and
kits), while other tests are automated and require only limited training to
perform). Typically, manually performed tests are authorized for use by
laboratories certified to perform high-complexity tests, while automated tests
are authorized for use by laboratories certified to perform moderate complexity
tests and/or at the point-of-care by facilities operating under a CLIA
Certificate of Waiver.
Major Companies
& their Molecular Diagnostic Products
Abbott RealTime
SARS-CoV-2 Assay is a real-time (RT) polymerase chain reaction (PCR) technology
for the qualitative detection of nucleic acids from the SARS-CoV-2 virus and
diagnosis of SARS-CoV-2 virus infection from individuals. It is a fully automated solution to help
laboratories to address the urgent need for automated, high-volume patient
testing during the Coronavirus (COVID-19) pandemic.
The NxTAG CoV Extended Panel detects SARS-CoV-2 detection using three viral genes (ORF1ab, E gene, and N gene). It provides sensitive and reliable results. It also provides a highly scalable and cost-effective solution.
Altona
Diagnostics:RealStar SARS-CoV-2 RT-PCR Kits (1.0 and
U.S versions)
RealStar SARS-CoV-2 RT-PCR Kits
(1.0 and U.S versions), is a reagent system, based on real-time PCR technology,
for the qualitative detection and differentiation of lineage B-betacoronavirus
(B-βCoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
specific RNA. These tests can be run in parallel with RealStarInfluenza
Screen & Type RT-PCR Kit 4.0.etc
Smart Detect SARS-CoV-2 rRTPCR
Kit is a real-time RT-PCR test for the
qualitative detection of nucleic acid from severe acute respiratory
syndrome-related coronavirus 2 in human nasopharyngeal, anterior nasal, and
mid-turbinate nasal swab specimens from individuals suspected of COVID-19
FDA Emergency Use Authorizations: Diagnostic Products Landscape
SPONSOR
PRODUCT
DESCRIPTION
Center for Disease Control and Prevention(CDC)
CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel
Developed by CDC and initially distributed to public health labs across the country Can only be run in high complexity labs
Wadsworth – New York State Public Health
New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel
Developed by Wadsworth based on CDC’s published protocol Run in qualified labs across New York State Can only be run in high complexity labs
Roche Molecular Systems, Inc.
cobas SARS-CoV-2 for use on the cobas 6800/8800 Systems
Commercially distributed as a kit to labs Can be run in moderate and high complexity labs
Life Technologies (a part of
Thermo Fisher Scientific, Inc.)
Commercially distributed as a kit to labs Can only be run in high complexity labs
Laboratory Corporation of America
COVID-19 RT-PCR Test COVID-19 RT-PCR Amendment
Developed and run in high complexity LabCorp labs only; not for broader lab distribution Amendment permits use of the Pixel by LabCorp COVID-19 test home collection kit allowing patients to self-collect nasal swab specimens at home The kit provides specimen collection materials and materials to safely mail specimens to an authorized laboratory
Hologic, Inc.
Panther Fusion SARS-CoV-2 Assay
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
Quest Diagnostics Infectious Disease, Inc.
SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR
Developed and run in Quest labs only; not a kit for distribution Can only be run in high complexity labs
Quidel Corporation
Lyra SARS-CoV-2 Assay
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
Abbott Molecular, Inc.
Abbott RealTime SARS-CoV-2 assay
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
GenMark Diagnostics, Inc.
ePlex SARS-CoV-2 Test
Reagents commercially distributed as a kit to labs Can run up to 24 specimens at the same time Can be run in a moderate or high complexity lab
DiaSorin Molecular LLC
Simplexa COVID-19 Direct
Reagents commercially distributed as a kit to labs Can run 1 specimen at a time Can be run in moderate and high complexity labs
Primerdesign Ltd.
Primerdesign Ltd COVID-19 genesig Real-Time PCR
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
Cepheid
Xpert Xpress SARS-CoV-2 test
Reagents commercially distributed as a kit to labs Can run up to 2,000 samples per day Can be run in a high or moderate complexity lab or at the Point of Care (POC) near the patient (deemed CLIA waived)
Mesa Biotech Inc
Accula SARS-CoV-2 Test
Reagents commercially distributed as a kit to labs Runs one specimen at a time Can be run in a high or moderate complexity lab or at the Point of Care (POC) near the patient (deemed CLIA waived)
BioFire Defense, LLC
BioFire COVID-19 Test
Reagents commercially distributed as a kit to labs Can run up to 264 tests per day Can be run in moderate or high complexity labs
PerkinElmer, Inc.
PerkinElmer New Coronavirus Nucleic Acid Detection kit
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
Avellino Labs USA
AvellinoCoV2 test
Developed and run in Avellino labs; not distributed to other labs High complexity test limited to authorized laboratories
BGI Genomics Co. Ltd.
Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019- nCoV
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
Luminex Molecular Diagnostics, Inc.
NxTAG CoV Extended Panel Assay
Reagents commercially distributed as a kit to labs Can only be run in high complexity labs
Abbott Diagnostics Scarborough, Inc.
ID NOW COVID-19
Reagents commercially distributed as a kit Requires a specific platform (ID NOW), of which there are 18,000 installed across the US Runs one specimen at a time
NeuMoDx Molecular, Inc
NeuMoDx SARS-CoV-2 Assay
Reagents commercially distributed as a kit Can run 288 or 96 samples at once, depending on the instrument, and takes 80 minutes per sample Can be run in high and moderate complexity labs
QIAGEN GmbH
QIAstat-Dx Respiratory SARSCoV-2 Panel
Detects multiple other respiratory viral and bacterial organisms Reagents commercially distributed as a kit to labs Runs one specimen at a time and takes one hour Can be run in high and moderate complexity labs
EUA for COVID-19 LDTs
Laboratory developed tests that are authorized are listed below and hyper link to letter granting inclusion under EUA
Authorizes the use of LDTs that meet certain criteria Authorized tests can be used in the high complexity CLIA-certified lab that developed the test
Ipsum Diagnostics
COV-19 IDx Assay
Uses commercially available reagents Can only be run in high complexity labs by Ipsum
Becton, Dickinson & Company (BD)
BioGX SARS-CoV-2 Reagents for BD MAX System
Reagents commercially distributed as a kit to labs Fully automated, 8 samples per hour Can be run in moderate and high complexity labs
Luminex Corporation
ARIES SARS-CoV-2 Assay
Reagents commercially distributed as a kit to labs Can be run in moderate and high complexity labs
The Telehealth includes the use of communications technology for providing the healthcare services for patients who are not visiting with their healthcare provider in person. The COVID-19 outbreak has interrupted the medicine and the delivery of healthcare worldwide. The urgency of the social distancing has increased the demand for telehealth for evaluating, managing, and tracking the COVID-19 patients without the necessity for the personal examination.
According to the CmaxInsight, the Telehealth has witnessed drastic growth due to the COVID-19 outbreak. The significant market growth is observed in the remote patient monitoring (RPM) segment and the virtual visits.
Benefits of Telehealth during the Coronavirus Outbreak
Eliminates the need for physical contact between patient and provider
Patients can schedule virtual visits easily
It is easy for the physicians to treat the patients virtually and tracking them through Remote Patient Monitoring
Medicines can be e-prescribed and adherence tracked
Several tools for self- examining the patients are available
Easy to gather and analyzed the patient-generated health data
It easily provides the essential services to patients who reside in areas that do not have enough primary care physicians or specialists
It can be used in a clinical trial or post-market (Phase 4) trial.
Mobile health (mHealth) devices or personal emergency response systems (PERS) can trigger alerts
These apps increase the coverage and communication with a patient
Opportunities for Telehealth Suppliers
Segments
Description
Virtual Visits
Remote evaluation of patients with symptoms or a known history of direct contact
RPM
Tracking of temperature & other biometric indicators for flagged patients
mHealth Wearables and Apps
Education & management of patients Monitoring the adherence of medications
PERS
Examining patient well-being and sleep patterns
Remote Consultation Services
Virtual meetings of medical experts for sharing the views
Data Analytics
Leveraging meeting media and content from third-party apps
Virtual Triaging
Determining which patients to visit first
Robotics
It is easy for the robotic attendants to enter the high-risk environments and to attend the patients as per the requirement
Major Telehealth Providers
Market Drivers
Ability to perform an accurate remote examination on the contagious patients
Availability of the Value-based reimbursements
Employee telehealth offerings at per-member, per month rates along with the usage rates
Novel Coronavirus (COVID-19) is the leading cause of mortality and morbidity worldwide. It has spread to more than 200 countries.
According to the World Health Organization (WHO) situation report (29 April 2020), the recent Epidemiology Insights are as follows:
The total number of confirmed
cases are more than 3million worldwide
More than 0.2 million died due
to the COVID-19
Major Countries Wise Epidemiology Insights (till date):
The United States accounts for the highest number of confirmed cases with 9,83,457 cases followed by Spain with 2,10,773 cases, Italy with 2,01,505 cases, and the UK with 1,61,149 cases
The highest number of new confirmed cases were observed in the United States with 22,541 cases, followed by the UK with 3,996 cases, and Italy with 2,091 cases
No new confirmed were observed in France
The highest number of death cases were observed in the United States with 50,492 deaths, followed by Italy with 27,359 deaths, Spain with 23,822 deaths and France with 23,627 deaths
The highest number of new death cases were observed in the United States with 1,322 cases, followed by Spain with 632 cases, the UK with 586 cases, and Italy with 382 cases
Every year, World Meningitis Day is celebrated on April 24, for raising awareness regarding the prevention, diagnosis, treatment of Meningitis. It also aims at providing and improving support for people affected by the Meningitis.
World Meningitis Day is led by the Confederation of Meningitis Organisations (COMO) involved in raising awareness as well as bringing healthcare practitioners, meningitis organizations, and survivors together from more than 35 countries. The organization advocates for meningitis vaccination worldwide.
Meningitis is an inflammation of the meninges, the membranes that cover the brain and spinal cord. The infected fluid surrounding the meninges leads to the development of Meningitis. It is characterized by signs and symptoms including fever, headache, vomiting, drowsy, confusion, rash, seizure, muscle & neck pain, and dislike of bright light. Meningitis is classified as viral meningitis, bacterial meningitis, fungal meningitis, parasitic meningitis, and non-infectious meningitis.
“Defeat Meningitis”
Facts about Meningitis
According to the Confederation of Meningitis Organizations, every year approximately 5 million people are suffering from meningitis worldwide. Every year around 300,000 people die due to Meningitis worldwide.
Viral meningitis is the most prevalent type of meningitis.
Multiple vaccines are needed for protection against different types of meningitis. Meningitis vaccines prevent tens of thousands of deaths every year.
Meningitis leaves around 1 in 5 people with an impairment including the cerebral palsy, depression, sight loss, organ damage, limb loss, brain injury, and hearing loss
Every year, the World Hemophilia Day is celebrated on 17 April to raise awareness regarding the hemophilia and other bleeding disorders.
World Hemophilia Day is an international awareness day for hemophilia and other bleeding disorders. Hemophilia is a serious bleeding disorder in which the blood does not clot normally which results in excessive bleeding. People with severe hemophilia may bleed for no reason.
World Hemophilia Day marks the birth anniversary of Frank
Schnabel, the founder of the World Federation of Hemophilia. It is an important
day for the World Federation of Hemophila (WFH) and the bleeding disorders
community.
This year the World Hemophilia Day is celebrated in a way that is sensitive to the risks of the current global novel coronavirus (COVID-19) pandemic. This year all the activities of this day will be observed virtually to the coronavirus spread.
Sanofi and GSK Collaborate to Develop Vaccine for COVID-19
Sanofi and GlaxoSmithKline
have signed a letter of intent to develop an adjuvanted vaccine for COVID-19,
using innovative technology. Sanofi would contribute its S-protein COVID-19
antigen, which is based on recombinant DNA technology whereas the GSK would contribute
its pandemic adjuvant technology. The use of an adjuvant technology would help
in reducing the amount of vaccine protein required per dose, allowing more
vaccine doses to be produced and therefore help in protecting the more people.
China Approves Two Experimental Coronavirus Vaccines to enter Clinical Trials
China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus. One vaccine is being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and another vaccine is being developed by the Wuhan Institute of Biological Products.
AstraZeneca to Test the Impact of Cancer Drug Calquence on Coronavirus Patients
AstraZeneca
is planning to start a clinical trial of its cancer drug i.e. Calquence to
assess its potential to control the exaggerated immune system response
associated with COVID-19 infection in severely ill patients.
Calquence
(acalabrutinib) belongs to a class of drugs called Bruton’s tyrosine kinase
(BTK) inhibitors which can suppress autoimmune diseases. Calquence is currently
used to treat certain types of blood cancers, has already been approved for the
treatment of adult patients with chronic lymphocytic leukaemia in the United States
and several other countries.
Celltrion Identifies Antibody Candidates against COVID-19
Celltrion has successfully selected the most potent antibody candidates to neutralise SARS-CoV-2, the virus causing COVID-19. Celltrion will begin cell-line development mass production of the selected therapeutic monoclonal antibody. The Company would conduct the efficacy and toxicity testing with Korea Centers for Disease Control and Prevention (KCDC) of the selected therapeutic monoclonal antibody in mice and non-human primates.
Immunomic collaborates with PharmaJet and EpiVax for COVID-19 Vaccine
Immunomic Therapeutics has entered into a collaboration with PharmaJet and EpiVax to develop a nucleic acid vaccine candidate against COVID-19. This collaboration would help in developing a vaccine that is scalable, heat-stable and easy to administer using PharmaJet’s Tropis needle-free injection system.
Vir selects Samsung Biologics to Produce COVID-19 Antibodies
Vir Biotechnology has selected South Korea-based Samsung Biologics for large-scale production of antibodies to potentially treat Covid-19. Under the terms of the collaboration, Samsung Biologics would provide the manufacturing services for Vir’s monoclonal antibody (mAb) programme targeting the novel coronavirus, SARS-CoV-2. Vir’s lead mAb candidates, VIR-7831 and VIR-7832, had showed high affinity for the spike protein of SARS-CoV-2 and ability
Eli Lilly to Begin Testing RA Drug Olumiant and
an Anti-Ang2 Drug in COVID-19 Patients
Eli Lilly plans to explore the use of its rheumatoid arthritis drug i.e., Olumiant (oral JAK1/JAK2 inhibitor) as a treatment for hospitalized patients with COVID-19. Olumiant (Baricitinib) is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. The clinical trial of Olumiant for COVID-19 would begin this month and results are expected within the next two months.
Moreover,
the company is planning to advance LY3127804, an investigational selective
monoclonal antibody against Angiopoietin 2 (Ang2), to Phase II testing in
pneumonia patients hospitalized with COVID-19 who are at a higher risk of
progressing to Acute Respiratory Distress Syndrome (ARDS). Ang2 is known to be
elevated in ARDS patients and Lilly will test whether inhibiting the effects of
Ang2 with a monoclonal antibody can reduce the progression to ARDS or the need
for mechanical ventilation in COVID-19 patients
Promising Clinical Trial Results of Gilead Sciences’ Antiviral Drug Remdesivir for COVID-19
Gilead Sciences Inc.’s experimental drug i.e. remdesivir has shown the promise results in early analysis. All the patients received remdesivir for up to 10 days on a compassionate use basis. The clinical trial demonstrated the clinical improvement was observed in 36 of 53 patients (68%) over the 18 days with 17 of the 30 patients on mechanical ventilation being able to get off the breathing device. Almost half of the patients studied were ultimately discharged, while 13% died. Mortality was highest among those who were on a ventilator, with 18% of them dying. Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy
FDA Approves Rutgers’ Saliva Test for COVID-19
The diagnostic saliva test developed by RUCDR Infinite Biologics with Spectrum Solutions and Accurate Diagnostic Labs (ADL) has received the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This test involves the use of the saliva for the diagnosis of the COVID-19.
This test has eliminated the need for collecting the sample through nasopharyngeal or oropharyngeal as the current COVID 19 diagnostic test requires a swab from deep in the nasal passages or the back of the throat. It puts the healthcare workers at risk of catching an infection. The diagnostic saliva test uses easy-to-collect saliva samples instead of the more difficult deep nose swabs in comparison to the existing diagnostic tests and would reduce the risk of healthcare workers from getting the infection.
Incorrect Recommendations or Information Regarding the Novel Coronavirus (COVID-19)
Now-a-days the several recommendations and information regarding the (COVID-19) coronavirus are being shared on social media including Facebook, WhatsApp, twitters, and others. A wide majority of these tips and information is based on false or unsubstantiated claims.
The Geneva health authorities have provided the list of the incorrect recommendations or information regarding the (COVID-19) coronavirus being shared. Here are the key list of these incorrect recommendations or information as follows:
Does a person without symptoms carrying the coronavirus is contagious?
According to the studies, people without symptoms are not the potential sources of contamination. The coronavirus infection spread mainly through respiratory droplets expelled by the people who cough. Sick people are most contagious when they are most symptomatic. There is no sufficient studies regarding the whether asymptomatic people infected with the new coronavirus are contagious or how long they are contagious before symptoms appear.
Will the virus die if exposed to temperatures of 26-27°C?
There are not any studies confirming that the climate or temperatures have an impact on the spread of coronavirus. Thus, it is impossible to say that spring or summer heat can literally kill a virus.
Does hot liquid neutralizes the virus?
It has been observed that drinking hot water or the frequency of water consumption has no effect on the coronavirus. It is not necessary to change the temperature of the water you drink. It is essential to drink water not just for killing the coronavirus.
Can coronavirus survive on inert surfaces for about 6 to 12 hours?
Various studies have shown that the coronaviruses can exist on surfaces from up to a few hours to several days depending on the different parameters such as surface type, temperature or humidity.
Does eating more ginger, garlic, pepper, etc. protects against coronavirus?
Eating ginger, garlic, pepper does not fight specifically against the coronavirus. These foods have virtues for the body.
One must hold your breath to find out if you are infected with the coronavirus. Holding one’s breath for more than 10 seconds without coughing, discomfort, congestion or tightness would prove that there is no fibrosis in the lungs and therefore no infection.
There is no scientific evidence to support this assertion. Only a laboratory test can confirm infection with the new coronavirus.
Does drinking water and gargling cure COVID-19?
Saltwater is effective in relieving the sore throat. People are advised to drink water to stay hydrated when they are sick with the flu or the novel coronavirus. Drinking does not eliminate the coronavirus in any way.
Dogs and cats can transmit the coronavirus?
There are not any studies demonstrating the transmission of the coronavirus through the dogs and cats.
Rinsing the nose regularly protects against coronavirus infection?
There are not any studies demonstrating the rinsing your nose with a saline solution protects against coronavirus infection.
Does coronavirus only affect vulnerable people?
Coronavirus can affect the people of any age-group. Elderly people and people with pre-existing conditions such as asthma, diabetes, chronic lung disease, cancer, heart disease, etc are at high risk of developing the coronavirus infection. Hence, people are advised to take measures to protect themselves from the virus through social distance of at least 2 meters, regular and meticulous hand washing, good respiratory hygiene, etc.
Are antibiotics effective in preventing and treating coronavirus infection?
Antibiotics do not work against viruses but are effective against only bacteria. The antibiotics should not be used as a means of prevention or treatment. If one is hospitalized for infection with CoV-2-CASR then one can receive antibiotics as the bacterial co-infection is possible.
CanChloroquine cures COVID-19?
There is no drug effective for the treatment of COVID-19. Some treatments are tested in numerous research protocols worldwide. Hence, Chloroquine treatment is currently reserved for patients in hospital settings or as part of a research protocol.
Are fabric masks an efficient substitute for surgical masks?
Fabric masks not efficient substitutes for surgical masks. In fact, surgical masks are the only masks where there is scientific data regarding filtration efficiency and airtightness. Fabric masks or other hand-made masks do not provide the bearer with any proven protection against coronavirus. Further, it is recommended that medical masks must be worn only by health staff members. FFP2 masks are required only if the presence of COVID-19 is suspected in a patient and if a high level of aerosol formation is expected during a medical procedure. Healthy people should not wear medical masks or surgical masks in the public. Healthy people must prefer fabric masks in the public.
The novel Coronavirus
(COVID2019) outbreak identified in China is causing global concern. It has
spread to more than 200 countries worldwide. According to the World Health
Organization (WHO)’s live report, there are more than 13,00,000 confirmed cases
of the novel Coronavirus (COVID-19) outbreak. Approximately, 74,306 number of
people died due to the novel Coronavirus. The United States accounts for
highest cases (363,321) followed by Spain (135,032), Italy (132,547), Germany
(99,225) China (83,157) and France (73,488).
There are no specific vaccines or treatments for COVID-19. Several clinical trials are undergoing for evaluating the potential treatments. Hence, it is essential to prevent Coronavirus infection and slowing the rate of transmission.
“Prevention is better than cure”
Preventive measures for Coronavirus are as
follows:
Wash Your
Hands
Wash your hands
regularly with soap and water, or clean them with alcohol-based hand rub
Avoid Close
Contact
Maintain at
least 1 metre distance with the people coughing or sneezing
Social
Distancing & Stay Home
Stay home and Practice
physical distancing by avoiding unnecessary travel and staying away from large
groups of people
Wear Facemask
Wear a facemask if you are sick
Cook Food
Cook food
thoroughly
Elbow Coughing
Use Elbow to cough
into it
Cleanliness
Clean frequently
touch surfaces daily
Cover
coughs and sneezes
Cover your mouth
and nose when coughing or sneezing
